ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: SA-PO1097

Use of Gentamicin-Citrate Lock Reduced Catheter-Related Bloodstream Infection Rates in Hemodialysis Patients: Results of a Natural Experiment

Session Information

  • Vascular Access - II
    November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 704 Dialysis: Vascular Access

Authors

  • Hussein, Wael F., Satellite Healthcare, San Jose, California, United States
  • Yang, Fang, Satellite Healthcare, San Jose, California, United States
  • Sun, Sumi J., Satellite Healthcare, San Jose, California, United States
  • Abra, Graham E., Satellite Healthcare, San Jose, California, United States
  • Schiller, Brigitte, Satellite Healthcare, San Jose, California, United States
Background

Use of central venous catheters (CVC) is a major risk factor for infections, a leading cause of morbidity and mortality in hemodialysis (HD) patients. Use of gentamicin 320 μg/mL in 4% sodium citrate lock (GCL) was previously shown to reduce the rate of CVC-related bloodstream infection (BSI). We report on the change of CVC-related BSI rates in four centers experiencing high BSI rates while using heparin catheter lock (period 1 [P1]) after switching to GCL (period 2 [P2]).

Methods

Retrospective observational study. Patient characteristics at time of switch to GCL were obtained from the provider’s EHR. CVC patient-months and reported events of CVC-related BSI were obtained from the NHSN database. The rate ratio for pooled rates for P2:P1 was calculated and tested for significance.

Results

There were 684 and 896 CVC patient-months in P1 and P2 respectively. Mean patient age was 64 ± 14 years, and 48% were female. Monthly CVC-related BSI rates are shown in Figure 1. Pooled CVC-related BSI rates were 2.8 and 0.6 per 100 patient-months for P1 and P2 respectively, representing an 80% reduction in the rate of BSI (rate ratio 0.20, 95% Confidence interval 0.08 – 0.54, p = 0.0004).

Conclusion

These results are consistent with results from a previous trial, but in real-practice setting. Use of the gentamicin-citrate lock significantly reduces CVC-related BSI.

Figure 1